Cancer

Natural product-derived CDK4/6 pathway blockade enhances the efficacy of Cancer immunotherapy: A pharmacological mixture encompassing natural products Monorden, Dihydroartemisinin, Lovostatin, Vorinostat (MDLV) and 5-FU (MDLV5FU)  inhibits the expression of cell cycle protein CDK4/CDK6, increases levels of T-III IFNs, inhibits the proliferation of Treg cells, decreases DNMT1 expression, inhibits the expression of a number of immune evasion molecules, increases antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target genes, 04/September/2017, 1.15 am
Natural product-derived CDK4/6 pathway blockade enhances the efficacy of Cancer immunotherapy: A pharmacological mixture encompassing natural products Monorden, Dihydroartemisinin, Lovostatin, Vorinostat (MDLV) and 5-FU (MDLV5FU)  inhibits the expression of cell cycle protein CDK4/CDK6, increases levels of T-III IFNs, inhibits the proliferation of Treg cells, decreases DNMT1 expression, inhibits the expression of a number of immune evasion molecules, increases antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target genes, 04/September/2017, 1.15 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction:What they say: A recent study from Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands has identified CMTM6 and CMTM4 as…

read more

Natural product-derived CDK4/6 pathway blockade enhances the efficacy of Cancer immunotherapy: A pharmacological mixture encompassing natural products Gambogic acid, Astaxanthin, Sulforphane, SAHA and Etoposide (GASSE) inhibits the expression of cell cycle protein CDK4/CDK6, increases levels of T-III IFNs, inhibits the proliferation of Treg cells, decreases DNMT1 expression, inhibits the expression of a number of immune evasion molecules, increases antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target genes, 3/September/2017, 1.57 am
Natural product-derived CDK4/6 pathway blockade enhances the efficacy of Cancer immunotherapy: A pharmacological mixture encompassing natural products Gambogic acid, Astaxanthin, Sulforphane, SAHA and Etoposide (GASSE) inhibits the expression of cell cycle protein CDK4/CDK6, increases levels of T-III IFNs, inhibits the proliferation of Treg cells, decreases DNMT1 expression, inhibits the expression of a number of immune evasion molecules, increases antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target genes, 3/September/2017, 1.57 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction:What they say: A recent study from Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands has identified CMTM6 and CMTM4 as…

read more

Natural product-derived therapy for metastasis: A pharmacological mixture encompassing NAC (N-Acetyl cysteine), Mangiferin, Berberine, Valproic acid, and Doxorubicin inhibits the expression of IL-6/8, decreases the expression of downstream molecules WASF3 and Arp2/3, suppresses tumor cell migration, reduces metastasis and prolongs survival via up regulation of its target gene, 3/September/2017, 1.43 am
Natural product-derived therapy for metastasis: A pharmacological mixture encompassing NAC (N-Acetyl cysteine), Mangiferin, Berberine, Valproic acid, and Doxorubicin inhibits the expression of IL-6/8, decreases the expression of downstream molecules WASF3 and Arp2/3, suppresses tumor cell migration, reduces metastasis and prolongs survival via up regulation of its target gene, 3/September/2017, 1.43 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from Department of Chemical and Biomolecular Engineering, The Johns Hopkins University, Baltimore, Maryland 21218, USA; Johns Hopkins Physical Sciences-Oncology Center, The Johns Hopkins University, Baltimore, Maryland…

read more

Natural product-derived therapy for Chronic Myeloid leukaemia (CML): A pharmacological mixture encompassing β-Cryptoxanthin and Nimbolide (CN) decreases the expression of Musashi2, inhibits cytosolic aminotransferase BCAT1 expression, decreases the intracellular production of BCAAs (Branched-chain amino acids), increases the expression of tumor suppressor genes, promotes differentiation of CML cells, and inhibits cancer progression in Myeloid leukemia via up-regulation of its target gene, 3/September/2017, 1.30 am
Natural product-derived therapy for Chronic Myeloid leukaemia (CML): A pharmacological mixture encompassing β-Cryptoxanthin and Nimbolide (CN) decreases the expression of Musashi2, inhibits cytosolic aminotransferase BCAT1 expression, decreases the intracellular production of BCAAs (Branched-chain amino acids), increases the expression of tumor suppressor genes, promotes differentiation of CML cells, and inhibits cancer progression in Myeloid leukemia via up-regulation of its target gene, 3/September/2017, 1.30 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Department of Biochemistry-Molecular Biology, Franklin College of Arts and Sciences, The University of Georgia, Athens, Georgia 30602, USA; and The University of…

read more

 Natural product-based PD-1 pathway blockade for Human cancer therapy: Lovastatin, a cholesterol lowering drug, decreases the expression of Glycogen synthase kinase-3β, increases transcription factor T-bet expression, decreases the abundance of co-inhibitory receptor PD-1 on the cell surface of Cytotoxic-T-cells, increases cytotoxic T lymphocyte function and augments anti-tumor activity, via up-regulation of its target gene, 1/September, 2017, 10.54 pm
 Natural product-based PD-1 pathway blockade for Human cancer therapy: Lovastatin, a cholesterol lowering drug, decreases the expression of Glycogen synthase kinase-3β, increases transcription factor T-bet expression, decreases the abundance of co-inhibitory receptor PD-1 on the cell surface of Cytotoxic-T-cells, increases cytotoxic T lymphocyte function and augments anti-tumor activity, via up-regulation of its target gene, 1/September, 2017, 10.54 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction:What they say:  A recent study from Cell Signalling Section, Division of Immunology, Department of Pathology, Tennis Court Road, University of Cambridge, Cambridge CB2 1QP, UK shows that “Glycogen Synthase Kinase 3 Inactivation Drives…

read more

Natural product-derived CDK4/6 pathway blockade enhances the efficacy of Cancer immunotherapy: A pharmacological mixture encompassing natural products Berberine, Nimbolide, N-Acetyl-cysteine (BNN) and the anticancer drug Doxorubicin(D) inhibits the expression of cell cycle protein CDK4/CDK6, increases levels of T-III IFNs, inhibits the proliferation of Treg cells, decreases DNMT1 expression, inhibits the expression of a number of immune evasion molecules, increases antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target genes, 31/August/2017, 1.33 am
Natural product-derived CDK4/6 pathway blockade enhances the efficacy of Cancer immunotherapy: A pharmacological mixture encompassing natural products Berberine, Nimbolide, N-Acetyl-cysteine (BNN) and the anticancer drug Doxorubicin(D) inhibits the expression of cell cycle protein CDK4/CDK6, increases levels of T-III IFNs, inhibits the proliferation of Treg cells, decreases DNMT1 expression, inhibits the expression of a number of immune evasion molecules, increases antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target genes, 31/August/2017, 1.33 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction:What they say: A recent study from Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands has identified CMTM6 and CMTM4 as…

read more
Start Typing